Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
31 March 2022Big PharmaMuireann Bolger

Gilead loses bid to quash parallel antitrust HIV lawsuit

Gilead Sciences has failed to prevent insurer Aetna from pursuing its lawsuit in a US state court, as it faces a spate of antitrust complaints alleging that it used pay-for-delay deals to maintain the high costs of HIV drugs.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Generics
Aetna gets antitrust suit moved back to state court
25 April 2022   American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.
Americas
Big pharma firm settles HIV drug disputes with generic makers
13 September 2022   Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Generics
Aetna gets antitrust suit moved back to state court
25 April 2022   American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.
Americas
Big pharma firm settles HIV drug disputes with generic makers
13 September 2022   Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

More on this story

Big Pharma
Antitrust HIV drugs case should be arbitrated, argue Gilead, BMS
16 February 2021   Gilead Sciences and Bristol-Myers Squibb have said that a suit alleging they were involved in a long-running scheme to block generic competition and keep HIV medication prices artificially high is “legally defective”.
Generics
Aetna gets antitrust suit moved back to state court
25 April 2022   American health care company Aetna has convinced a California court to transfer its antitrust action claiming that Gilead and other drugmakers used pay-for-delay tactics to maintain high costs of HIV treatments.
Americas
Big pharma firm settles HIV drug disputes with generic makers
13 September 2022   Gilead had filed patent infringement proceedings lawsuit against five companies | Drug makers will receive non-exclusive licences starting from Halloween 2031.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility